Tokyo Tape
Sign in
← Alfresa Holdings

Half-year report · Q2

2784.TEDINET S100UPC8
Period2024-04-01 → 2024-09-30
Filed2024-11-12
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
MetricValuePeriodScopeSource row
Revenue¥1.46T2024-04-01 → 2024-09-30Cons.Net sales
Revenue¥2.86T2023-04-01 → 2024-03-31Cons.Net sales (5-year summary)
Revenue¥1.43T2023-04-01 → 2023-09-30Cons.Net sales
Operating income¥15.0bn2024-04-01 → 2024-09-30Cons.Operating income
Operating income¥16.0bn2023-04-01 → 2023-09-30Cons.Operating income
Ordinary income¥16.3bn2024-04-01 → 2024-09-30Cons.Ordinary income
Ordinary income¥40.0bn2023-04-01 → 2024-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥17.3bn2023-04-01 → 2023-09-30Cons.Ordinary income
Profit before tax¥20.7bn2024-04-01 → 2024-09-30Cons.Income before income taxes
Profit before tax¥17.4bn2023-04-01 → 2023-09-30Cons.Income before income taxes
Net income (owners)¥14.1bn2024-04-01 → 2024-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥29.6bn2023-04-01 → 2024-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥11.8bn2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent
Net income¥13.8bn2024-04-01 → 2024-09-30Cons.Profit loss
Net income¥11.9bn2023-04-01 → 2023-09-30Cons.Profit loss
Total assets¥1.47Tat 2024-09-30Cons.Assets
Total assets¥1.45Tat 2024-03-31Cons.Assets
Total assets¥1.43Tat 2023-09-30Cons.Total assets (5-year summary)
Total liabilities¥975.8bnat 2024-09-30Cons.Liabilities
Total liabilities¥967.8bnat 2024-03-31Cons.Liabilities
Net assets / equity¥491.3bnat 2024-09-30Cons.Net assets
Net assets / equity¥479.9bnat 2024-03-31Cons.Net assets
Net assets / equity¥465.6bnat 2023-09-30Cons.Net assets (5-year summary)
Cash and deposits¥206.8bnat 2024-09-30Cons.Cash and deposits
Cash and deposits¥213.8bnat 2024-03-31Cons.Cash and deposits
Cash & equivalents¥204.6bnat 2024-09-30Cons.Cash and cash equivalents
Cash & equivalents¥212.3bnat 2024-03-31Cons.Cash and cash equivalents
Cash & equivalents¥184.8bnat 2023-09-30Cons.Cash and cash equivalents
Cash & equivalents¥158.8bnat 2023-03-31dCons.Cash and cash equivalents
Operating cash flow¥2.9bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥86.4bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥63.1bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥8.4bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥14.2bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥8.7bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥7.5bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥19.7bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥29.5bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥75.262024-04-01 → 2024-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥154.132023-04-01 → 2024-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥60.292023-04-01 → 2023-09-30Cons.Basic earnings loss per share (5-year summary)
Equity ratio33.5%at 2024-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio33.1%at 2024-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio32.6%at 2023-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 44
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2024-04-01 → 2024-09-30−¥18.0bn
Reconciling Itemsreconcilingrevenue intersegment2024-04-01 → 2024-09-30−¥18.0bn
Reconciling Itemsreconcilingsegment profit2024-04-01 → 2024-09-30¥174m
jpcrp040300-q2r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentrevenue2024-04-01 → 2024-09-30¥1.30T
jpcrp040300-q2r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentrevenue external2024-04-01 → 2024-09-30¥1.29T
jpcrp040300-q2r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥9.6bn
jpcrp040300-q2r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentsegment profit2024-04-01 → 2024-09-30¥12.7bn
jpcrp040300-q2r_E02962-000Manufacturing Businessreportable segmentrevenue2024-04-01 → 2024-09-30¥27.0bn
jpcrp040300-q2r_E02962-000Manufacturing Businessreportable segmentrevenue external2024-04-01 → 2024-09-30¥18.9bn
jpcrp040300-q2r_E02962-000Manufacturing Businessreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥8.1bn
jpcrp040300-q2r_E02962-000Manufacturing Businessreportable segmentsegment profit2024-04-01 → 2024-09-30¥188m
jpcrp040300-q2r_E02962-000Medical Related Businessreportable segmentrevenue2024-04-01 → 2024-09-30¥18.4bn
jpcrp040300-q2r_E02962-000Medical Related Businessreportable segmentrevenue external2024-04-01 → 2024-09-30¥18.4bn
jpcrp040300-q2r_E02962-000Medical Related Businessreportable segmentsegment profit2024-04-01 → 2024-09-30¥248m
jpcrp040300-q2r_E02962-000Self Medication Products Wholesaling Businessreportable segmentrevenue2024-04-01 → 2024-09-30¥132.4bn
jpcrp040300-q2r_E02962-000Self Medication Products Wholesaling Businessreportable segmentrevenue external2024-04-01 → 2024-09-30¥132.1bn
jpcrp040300-q2r_E02962-000Self Medication Products Wholesaling Businessreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥258m
jpcrp040300-q2r_E02962-000Self Medication Products Wholesaling Businessreportable segmentsegment profit2024-04-01 → 2024-09-30¥1.7bn
Total Of Reportable Segments And Otherssegment totalrevenue2024-04-01 → 2024-09-30¥1.47T
Total Of Reportable Segments And Otherssegment totalrevenue external2024-04-01 → 2024-09-30¥1.46T
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2024-04-01 → 2024-09-30¥18.0bn
Total Of Reportable Segments And Otherssegment totalsegment profit2024-04-01 → 2024-09-30¥14.8bn
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-09-30−¥16.9bn
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-09-30−¥16.9bn
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-09-30¥269m
jpcrp040300-q2r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥1.27T
jpcrp040300-q2r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥1.26T
jpcrp040300-q2r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥8.9bn
jpcrp040300-q2r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentsegment profit2023-04-01 → 2023-09-30¥13.8bn
jpcrp040300-q2r_E02962-000Manufacturing Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥26.0bn
jpcrp040300-q2r_E02962-000Manufacturing Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥18.3bn
jpcrp040300-q2r_E02962-000Manufacturing Businessreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥7.7bn
jpcrp040300-q2r_E02962-000Manufacturing Businessreportable segmentsegment profit2023-04-01 → 2023-09-30¥186m
jpcrp040300-q2r_E02962-000Medical Related Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥18.2bn
jpcrp040300-q2r_E02962-000Medical Related Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥18.2bn
jpcrp040300-q2r_E02962-000Medical Related Businessreportable segmentsegment profit2023-04-01 → 2023-09-30¥279m
jpcrp040300-q2r_E02962-000Self Medication Products Wholesaling Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥133.3bn
jpcrp040300-q2r_E02962-000Self Medication Products Wholesaling Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥133.1bn
jpcrp040300-q2r_E02962-000Self Medication Products Wholesaling Businessreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥275m
jpcrp040300-q2r_E02962-000Self Medication Products Wholesaling Businessreportable segmentsegment profit2023-04-01 → 2023-09-30¥1.5bn
Total Of Reportable Segments And Otherssegment totalrevenue2023-04-01 → 2023-09-30¥1.44T
Total Of Reportable Segments And Otherssegment totalrevenue external2023-04-01 → 2023-09-30¥1.43T
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2023-04-01 → 2023-09-30¥16.9bn
Total Of Reportable Segments And Otherssegment totalsegment profit2023-04-01 → 2023-09-30¥15.7bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 562
ItemContextValueUnit
Cancellation penalty elCurrentYTDDuration839000000JPY
Extraordinary lossPrior1YTDDuration109000000JPY
Extraordinary lossCurrentYTDDuration1924000000JPY
Income before income taxesPrior1YTDDuration17356000000JPY
Income before income taxesCurrentYTDDuration20669000000JPY
Income taxes currentPrior1YTDDuration7630000000JPY
Income taxes currentCurrentYTDDuration10333000000JPY
Income taxes deferredPrior1YTDDuration-2163000000JPY
Income taxes deferredCurrentYTDDuration-3433000000JPY
Income taxesPrior1YTDDuration5466000000JPY
Income taxesCurrentYTDDuration6899000000JPY
Profit lossPrior1YTDDuration11889000000JPY
Profit lossCurrentYTDDuration13769000000JPY
Profit loss attributable to owners of parentPrior1YTDDuration11850000000JPY
Profit loss attributable to owners of parentCurrentYTDDuration14065000000JPY
Profit loss attributable to non controlling interestsPrior1YTDDuration38000000JPY
Profit loss attributable to non controlling interestsCurrentYTDDuration-295000000JPY
Valuation difference on available for sale securities net of tax ociPrior1YTDDuration5583000000JPY
Valuation difference on available for sale securities net of tax ociCurrentYTDDuration4084000000JPY
Deferred gains or losses on hedges net of tax ociPrior1YTDDuration0JPY
Deferred gains or losses on hedges net of tax ociCurrentYTDDuration-5000000JPY
Foreign currency translation adjustment net of tax ociPrior1YTDDuration63000000JPY
Foreign currency translation adjustment net of tax ociCurrentYTDDuration203000000JPY
Remeasurements of defined benefit plans net of tax ociPrior1YTDDuration-218000000JPY
Remeasurements of defined benefit plans net of tax ociCurrentYTDDuration-281000000JPY
Other comprehensive incomePrior1YTDDuration5428000000JPY
Other comprehensive incomeCurrentYTDDuration4000000000JPY
Comprehensive incomePrior1YTDDuration17317000000JPY
Comprehensive incomeCurrentYTDDuration17769000000JPY
Comprehensive income attributable to owners of the parentPrior1YTDDuration17279000000JPY
Comprehensive income attributable to owners of the parentCurrentYTDDuration18065000000JPY
Comprehensive income attributable to non controlling interestsPrior1YTDDuration38000000JPY
Comprehensive income attributable to non controlling interestsCurrentYTDDuration-295000000JPY
Income before income taxesPrior1YTDDuration17356000000JPY
Income before income taxesCurrentYTDDuration20669000000JPY
Depreciation and amortization ope cfPrior1YTDDuration6418000000JPY
Depreciation and amortization ope cfCurrentYTDDuration7133000000JPY
Impairment loss ope cfPrior1YTDDuration4000000JPY
Impairment loss ope cfCurrentYTDDuration48000000JPY
Amortization of goodwill ope cfPrior1YTDDuration248000000JPY
Amortization of goodwill ope cfCurrentYTDDuration249000000JPY
Increase decrease in allowance for doubtful accounts ope cfPrior1YTDDuration-136000000JPY
Increase decrease in allowance for doubtful accounts ope cfCurrentYTDDuration-1000000000JPY
Increase decrease in provision for bonuses ope cfPrior1YTDDuration-1027000000JPY
Increase decrease in provision for bonuses ope cfCurrentYTDDuration-865000000JPY
Increase decrease in provision for directors bonuses ope cfPrior1YTDDuration-196000000JPY
Increase decrease in provision for directors bonuses ope cfCurrentYTDDuration-262000000JPY
Increase decrease in net defined benefit liability ope cfPrior1YTDDuration-542000000JPY
Increase decrease in net defined benefit liability ope cfCurrentYTDDuration-816000000JPY
Interest and dividends income ope cfPrior1YTDDuration-807000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2024-03-31pass
balance sheet identityconsolidated 2024-09-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2024-03-31pass
statement vs summary · net assetsconsolidated 2024-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2024-04-01/2024-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2024-04-01/2024-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2024-04-01/2024-09-30pass
statement vs summary · total assetsconsolidated 2024-03-31pass
statement vs summary · total assetsconsolidated 2024-09-30pass